Precision Medicine and/or Biomarker Based Therapy in T2DM

Precision Medicine and/or Biomarker Based Therapy in T2DM: Ready for Prime Time?

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

Precision Medicine and/or Biomarker Based Therapy in T2DM : Ready for Prime Time? / Rossing, Peter; Frimodt-Møller, Marie; Persson, Frederik.

I: Seminars in Nephrology, Bind 43, Nr. 3, 151430, 2023.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Rossing, P, Frimodt-Møller, M & Persson, F 2023, 'Precision Medicine and/or Biomarker Based Therapy in T2DM: Ready for Prime Time?', Seminars in Nephrology, bind 43, nr. 3, 151430. https://doi.org/10.1016/j.semnephrol.2023.151430

APA

Rossing, P., Frimodt-Møller, M., & Persson, F. (2023). Precision Medicine and/or Biomarker Based Therapy in T2DM: Ready for Prime Time? Seminars in Nephrology, 43(3), [151430]. https://doi.org/10.1016/j.semnephrol.2023.151430

Vancouver

Rossing P, Frimodt-Møller M, Persson F. Precision Medicine and/or Biomarker Based Therapy in T2DM: Ready for Prime Time? Seminars in Nephrology. 2023;43(3). 151430. https://doi.org/10.1016/j.semnephrol.2023.151430

Author

Rossing, Peter ; Frimodt-Møller, Marie ; Persson, Frederik. / Precision Medicine and/or Biomarker Based Therapy in T2DM : Ready for Prime Time?. I: Seminars in Nephrology. 2023 ; Bind 43, Nr. 3.

Bibtex

@article{b42ed9ac4b73473e847bacbd20852553,

title = "Precision Medicine and/or Biomarker Based Therapy in T2DM: Ready for Prime Time?",

abstract = "Approximately 30-40% of people with type 2 diabetes mellitus develop chronic kidney disease. This is characterised by elevated blood pressure, declining kidney function and enhanced cardiovascular morbidity and mortality. Increased albuminuria and decreasing estimated glomerular function has to be evaluated regularly to diagsnose kidney disease. New biomarkers may facilitate early diagnosis and provide infomation on undlying pathology thereby supporting early precision intervention for the optimal benefit. A number of biomarkers have been suggested but are not yet implemented in clinical practice. iI the future such bimarkers may pave the way for personalized treatment.",

keywords = "Humans, Diabetes Mellitus, Type 2/drug therapy, Precision Medicine, Renal Insufficiency, Chronic/diagnosis, Hypertension, Biomarkers, Albuminuria/diagnosis, Glomerular Filtration Rate, Diabetic Nephropathies/diagnosis",

author = "Peter Rossing and Marie Frimodt-M{\o}ller and Frederik Persson",

year = "2023",

doi = "10.1016/j.semnephrol.2023.151430",

language = "English",

volume = "43",

journal = "Seminars in Nephrology",

issn = "0270-9295",

publisher = "W.B.Saunders Co.",

number = "3",

}

RIS

TY - JOUR

T1 - Precision Medicine and/or Biomarker Based Therapy in T2DM

T2 - Ready for Prime Time?

AU - Rossing, Peter

AU - Frimodt-Møller, Marie

AU - Persson, Frederik

PY - 2023

Y1 - 2023

N2 - Approximately 30-40% of people with type 2 diabetes mellitus develop chronic kidney disease. This is characterised by elevated blood pressure, declining kidney function and enhanced cardiovascular morbidity and mortality. Increased albuminuria and decreasing estimated glomerular function has to be evaluated regularly to diagsnose kidney disease. New biomarkers may facilitate early diagnosis and provide infomation on undlying pathology thereby supporting early precision intervention for the optimal benefit. A number of biomarkers have been suggested but are not yet implemented in clinical practice. iI the future such bimarkers may pave the way for personalized treatment.

AB - Approximately 30-40% of people with type 2 diabetes mellitus develop chronic kidney disease. This is characterised by elevated blood pressure, declining kidney function and enhanced cardiovascular morbidity and mortality. Increased albuminuria and decreasing estimated glomerular function has to be evaluated regularly to diagsnose kidney disease. New biomarkers may facilitate early diagnosis and provide infomation on undlying pathology thereby supporting early precision intervention for the optimal benefit. A number of biomarkers have been suggested but are not yet implemented in clinical practice. iI the future such bimarkers may pave the way for personalized treatment.

KW - Humans

KW - Diabetes Mellitus, Type 2/drug therapy

KW - Precision Medicine

KW - Renal Insufficiency, Chronic/diagnosis

KW - Hypertension

KW - Biomarkers

KW - Albuminuria/diagnosis

KW - Glomerular Filtration Rate

KW - Diabetic Nephropathies/diagnosis

U2 - 10.1016/j.semnephrol.2023.151430

DO - 10.1016/j.semnephrol.2023.151430

M3 - Review

C2 - 37862744

VL - 43

JO - Seminars in Nephrology

JF - Seminars in Nephrology

SN - 0270-9295

IS - 3

M1 - 151430

ER -

ID: 381063649